Aafke H. Honkoop

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

Walter Taal, Hendrika M. Oosterkamp, Annemiek Walenkamp et al. · The Lancet Oncology · 2014 · 753 citations

Medicine, Oncology, Pharmacotherapy +16

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial

Miriam Koopman, Ninja Antonini, Joep Douma et al. · The Lancet · 2007 · 631 citations

Medicine, Oncology, Pharmacology +12

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial

Mette S. van Ramshorst, Anna van der Voort, Erik van Werkhoven et al. · The Lancet Oncology · 2018 · 445 citations · Full text

Medicine, Oncology, Breast Oncology +15

Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial

Stefanie de Groot, Rieneke T. Lugtenberg, Danielle Cohen et al. · Nature Communications · 2020 · 335 citations · Full text

Medicine, Nutritional Sciences, Oncology +17

Angiotensin II–Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer

Annelies H. Boekhout, Jourik A. Gietema, Bojana Milojkovic Kerklaan et al. · JAMA Oncology · 2016 · 199 citations · Full text

Medicine, Oncology, Pharmacology +17